Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Healthcare Triangle (HCTI) Research & Development (2020 - 2025)

Healthcare Triangle's Research & Development history spans 6 years, with the latest figure at $59000.0 for Q3 2025.

  • For Q3 2025, Research & Development fell 66.29% year-over-year to $59000.0; the TTM value through Sep 2025 reached $178000.0, down 70.96%, while the annual FY2024 figure was $429000.0, 46.31% down from the prior year.
  • Research & Development for Q3 2025 was $59000.0 at Healthcare Triangle, up from $55000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $2.8 million in Q4 2022 and bottomed at -$80000.0 in Q4 2024.
  • The 5-year median for Research & Development is $207000.0 (2024), against an average of $668263.2.
  • The largest annual shift saw Research & Development soared 300.61% in 2021 before it tumbled 176.92% in 2024.
  • A 5-year view of Research & Development shows it stood at $1.5 million in 2021, then soared by 86.98% to $2.8 million in 2022, then plummeted by 96.25% to $104000.0 in 2023, then crashed by 176.92% to -$80000.0 in 2024, then skyrocketed by 173.75% to $59000.0 in 2025.
  • Per Business Quant, the three most recent readings for HCTI's Research & Development are $59000.0 (Q3 2025), $55000.0 (Q2 2025), and $144000.0 (Q1 2025).